Skip to contentX
Xenon Pharmaceuticals Inc.
X
XENEXenon Pharmaceuticals Inc. Q2 2020 · 10-Q
Revenue$13.38M$13.38Mno prior Q2 2019 on file Net Income-$175.00K-$175.00KN/M vs Q2 2019 EPS Diluted$0.00$0.00N/M vs Q2 2019 Operating Income-$646,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Xenon Pharmaceuticals Inc. · CIK 1582313 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$11,158,000N/M Margins · derivedOperating margin-4.8%
Net margin-1.3%
ended Jun 30, 2020 · filed Aug 6, 2020 · 37 d after period end